Oncology Times - OncTimes Talk

Unknown

4,3 (3)
НАУКА
КАЖДЫЕ ДВЕ НЕДЕЛИ

OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.

25 ЯНВ.

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

Oncology Times - OncTimes Talk

8 мин.
13 ЯНВ.

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

Oncology Times - OncTimes Talk

16 мин.
10 ЯНВ.

Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development

Oncology Times - OncTimes Talk

9 мин.
10 ЯНВ.

Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma

Oncology Times - OncTimes Talk

7 мин.
10 ЯНВ.

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

Oncology Times - OncTimes Talk

8 мин.
10 ЯНВ.

Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer

Oncology Times - OncTimes Talk

7 мин.
31.12.2024

The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front

Oncology Times - OncTimes Talk

14 мин.
25.12.2024

Digital Twin Brings AI Power to Individualize Cancer Management

Oncology Times - OncTimes Talk

12 мин.

См. все (185)

4,3

из 5

Оценок: 3

OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.

Автор

Unknown
Годы выхода

2012 - 2025
Выпуски

185
Ограничения

Без ненормативной лексики
Сайт подкаста

Oncology Times - OncTimes Talk

Карьера

Карьера

Еженедельно
Здоровье и фитнес

Здоровье и фитнес

Каждые две недели

Oncology Times - OncTimes Talk

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development

Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer

The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front

Digital Twin Brings AI Power to Individualize Cancer Management

Оценки и отзывы

Об этом подкасте

Информация

Вам может также понравиться

Oncology Times - OncTimes Talk

Выпуски

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development

Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified

Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer

The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front

Digital Twin Brings AI Power to Individualize Cancer Management

Оценки и отзывы

Об этом подкасте

Информация

Вам может также понравиться